Dr. Arlene Siefker-Radtke on FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.I agreeRead More
